Jane Street’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $977K | Sell |
44,900
-73,500
| -62% | -$1.42M | ﹤0.01% | 6542 |
|
|
2025
Q4 | $2.55M | Sell |
118,400
-44,100
| -27% | -$929K | ﹤0.01% | 4363 |
|
|
2025
Q3 | $3.13M | Sell |
162,500
-342,200
| -68% | -$6.1M | ﹤0.01% | 4147 |
|
|
2025
Q2 | $8.63M | Buy |
504,700
+338,400
| +203% | +$14.4M | ﹤0.01% | 2320 |
|
|
2025
Q1 | $10.6M | Buy |
166,300
+76,000
| +84% | +$8M | ﹤0.01% | 1920 |
|
|
2024
Q4 | $11M | Buy |
90,300
+16,500
| +22% | +$2.02M | ﹤0.01% | 1796 |
|
|
2024
Q3 | $9.22M | Sell |
73,800
-145,200
| -66% | -$20.1M | ﹤0.01% | 1990 |
|
|
2024
Q2 | $34.6M | Buy |
219,000
+138,500
| +172% | +$17.8M | 0.01% | 894 |
|
|
2024
Q1 | $10.4M | Sell |
80,500
-176,100
| -69% | -$21.6M | ﹤0.01% | 1768 |
|
|
2023
Q4 | $24.7M | Buy |
256,600
+58,200
| +29% | +$5.58M | 0.01% | 1100 |
|
|
2023
Q3 | $24.1M | Buy |
198,400
+141,800
| +251% | +$16M | 0.01% | 961 |
|
|
2023
Q2 | $6.48M | Sell |
56,600
-215,600
| -79% | -$27.8M | ﹤0.01% | 2402 |
|
|
2023
Q1 | $37.5M | Buy |
272,200
+130,300
| +92% | +$16.9M | 0.02% | 642 |
|
|
2022
Q4 | $18.4M | Sell |
141,900
-48,000
| -25% | -$5.56M | 0.01% | 1075 |
|
|
2022
Q3 | $21M | Buy |
189,900
+88,900
| +88% | +$8.96M | 0.01% | 1026 |
|
|
2022
Q2 | $7.57M | Sell |
101,000
-42,400
| -30% | -$3.12M | ﹤0.01% | 2083 |
|
|
2022
Q1 | $11.2M | Sell |
143,400
-4,600
| -3% | -$352K | ﹤0.01% | 1857 |
|
|
2021
Q4 | $13.3M | Buy |
148,000
+79,400
| +116% | +$6.79M | ﹤0.01% | 1557 |
|
|
2021
Q3 | $6.34M | Sell |
68,600
-32,600
| -32% | -$2.51M | ﹤0.01% | 2390 |
|
|
2021
Q2 | $7.87M | Sell |
101,200
-63,800
| -39% | -$4.84M | ﹤0.01% | 2001 |
|
|
2021
Q1 | $12.3M | Sell |
165,000
-143,400
| -46% | -$13.2M | 0.01% | 1361 |
|
|
2020
Q4 | $52.6M | Buy |
308,400
+64,800
| +27% | +$9.6M | 0.03% | 437 |
|
|
2020
Q3 | $34.2M | Buy |
243,600
+16,900
| +7% | +$2.57M | 0.02% | 522 |
|
|
2020
Q2 | $36.3M | Buy |
226,700
+198,000
| +690% | +$26.9M | 0.03% | 472 |
|
|
2020
Q1 | $2.81M | Sell |
28,700
-123,400
| -81% | -$14.1M | ﹤0.01% | 1682 |
|
|
2019
Q4 | $19.6M | Buy |
152,100
+99,600
| +190% | +$10.1M | 0.03% | 387 |
|
|
2019
Q3 | $3.95M | Buy |
52,500
+24,200
| +86% | +$2.86M | 0.01% | 1166 |
|
|
2019
Q2 | $4.3M | Sell |
28,300
-58,700
| -67% | -$7.13M | 0.01% | 1166 |
|
|
2019
Q1 | $10.4M | Buy |
87,000
+67,200
| +339% | +$8.64M | 0.02% | 666 |
|
|
2018
Q4 | $2.16M | Buy |
19,800
+6,900
| +53% | +$863K | ﹤0.01% | 1648 |
|
|
2018
Q3 | $2.08M | Buy |
12,900
+3,100
| +32% | +$424K | ﹤0.01% | 1855 |
|
|
2018
Q2 | $1.29M | Sell |
9,800
-5,200
| -35% | -$490K | ﹤0.01% | 2428 |
|
|
2018
Q1 | $1.11M | Sell |
15,000
-43,400
| -74% | -$2.89M | ﹤0.01% | 2531 |
|
|
2017
Q4 | $3.25M | Sell |
58,400
-5,500
| -9% | -$291K | 0.01% | 1168 |
|
|
2017
Q3 | $2.9M | Buy |
+63,900
| New | +$2.55M | 0.01% | 1284 |
|
|
2017
Q2 | – | Sell |
-30,500
| Closed | -$903K | – | 4841 |
|
|
2017
Q1 | $903K | Sell |
30,500
-83,300
| -73% | -$2.58M | ﹤0.01% | 2171 |
|
|
2016
Q4 | $3.12M | Sell |
113,800
-102,600
| -47% | -$4.12M | 0.01% | 970 |
|
|
2016
Q3 | $13.3M | Sell |
216,400
-88,700
| -29% | -$2.68M | 0.06% | 246 |
|
|
2016
Q2 | $5.82M | Buy |
305,100
+261,400
| +598% | +$4.84M | 0.03% | 561 |
|
|
2016
Q1 | $853K | Buy |
43,700
+37,000
| +552% | +$646K | ﹤0.01% | 2002 |
|
|
2015
Q4 | $258K | Sell |
6,700
-22,300
| -77% | -$723K | ﹤0.01% | 3289 |
|
|
2015
Q3 | $931K | Buy |
29,000
+21,000
| +263% | +$713K | 0.01% | 1694 |
|
|
2015
Q2 | $243K | Buy |
+8,000
| New | +$164K | ﹤0.01% | 3063 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
Jane Street's SRPT Position: Q1 2026 in Review
Jane Street opened a new position in Sarepta Therapeutics (SRPT) in Q1 2026: 187,709 shares worth $4.08M. The stake represents ﹤0.01% of the portfolio and ranks #3813 among its holdings. This is a return to the name: Jane Street previously reported a position in SRPT as recently as Q2 2025.
Jane Street first reported a position in SRPT in Q2 2013 and has held it in 45 quarters since. The position peaked at $137M in Q2 2024. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Jane Street held 187,709 shares of Sarepta Therapeutics worth $4.08M as of Q1 2026.
- Sarepta Therapeutics was a new Jane Street position in Q1 2026.
- Sarepta Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3813 holding.
- Jane Street first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 45 quarters since.
- Jane Street's Sarepta Therapeutics position peaked at $137M in Q2 2024.
- 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.